The Central Hospital of Wuhan
Wuhan 430014
7 studies enrolling now · 13 studies all time
What they study most
Acute Coronary Syndrome, Acute Myocardial Infarction, Atrial Fibrillation, Castration-Resistant Prostatic Cancer, Chronic Kidney Disease, Colitis, Ulcerative, Crohn Disease, Crohn's Disease, Ischemic Stroke; Ischemic Attack, Transient, Moderately to Severely Active Crohns Disease, Obesity, Overweight
Studies at this site
- A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin — Recruiting now
- A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease — Recruiting now
- A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis — Recruiting now
- A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer — Recruiting now
- A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease — Recruiting now
- A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE — Running, not enrolling
- A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer — Running, not enrolling
- Selatogrel Outcome Study in Suspected Acute Myocardial Infarction — Enrolling by invitation
- A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome — Completed
- A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation — Running, not enrolling
- A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease — Running, not enrolling
- A Phase II Study of H021 Enteric-coated Tablets for Moderately to Severely Active Crohn's Disease — Starting soon
- EMPA-KIDNEY (The Study of Heart and Kidney Protection With Empagliflozin) — Completed